Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project
Date
2017Language
en
Keyword
Abstract
Background and objective Diabetes mellitus is associated with an increased risk of stroke and poor outcome following a stroke event. We assessed the impact of discharge treatment with aspirin versus clopidogrel on the 10-year survival of patients with type 2 diabetes after a first-ever noncardioembolic acute ischemic stroke (AIS). Methods This was a post hoc analysis of the Athens Stroke Outcome Project. Study outcomes included death, stroke recurrence, and a composite cardiovascular disease (CVD) end point (recurrent stroke, myocardial infarction, unstable angina, coronary revascularization, aortic aneurysm rupture, or sudden death). Kaplan–Meier survival curve and Cox regression analyses were performed. Results A total of 304 (93 women) diabetic patients receiving either aspirin (n = 197) or clopidogrel (n = 107) were studied. The 10-year survival was better in clopidogrel-treated patients than in aspirin-treated patients (19 deaths [17.7%] for clopidogrel versus 55 deaths [27.9%] for aspirin; log-rank test: 4.91, P =.027). Similarly, clopidogrel was associated with a favorable impact on recurrent stroke (12 events [11.2%] for clopidogrel versus 39 events [19.7%] for aspirin; log-rank test: 4.46, P =.035) and on the composite CVD end point (21 events [19.6%] for clopidogrel versus 54 events [27.4%] for aspirin; log-rank test: 4.17, P =.041). In the multivariable analysis, the beneficial effect of clopidogrel over aspirin on both primary and secondary end points was independent of age, gender, the presence of CVD or CVD risk factors, and stroke severity. Conclusions Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS. © 2017 National Stroke Association
Collections
Related items
Showing items related by title, author, creator and subject.
-
Acute limb ischemia and anticoagulation in patients with history of atrial fibrillation
Spanos K., Athanasoulas A., Argyriou C., Vassilopoulos I., Giannoukas A.D. (2016)BACKGROUND: Atrial fibrillation (AF) is the commonest source of arterial embolization causing acute limb ischemia (ALI). The aim of this study was to assess the adherence of anticoagulation in AF patients and the treatment ... -
Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: A multicenter, case-control study
Panopoulos S., Thomas K., Georgiopoulos G., Boumpas D., Katsiari C., Bertsias G., Drosos A.A., Boki K., Dimitroulas T., Garyfallos A., Papagoras C., Katsimbri P., Tziortziotis A., Adamichou C., Kaltsonoudis E., Argyriou E., Vosvotekas G., Sfikakis P.P., Vassilopoulos D., Tektonidou M.G. (2021)Objectives: Evidence on comorbidity prevalence in antiphospholipid syndrome (APS) and its difference from high comorbidity burden rheumatic diseases is limited. Herein, we compare multiple comorbidities between APS and RA. ... -
The contribution of genetic variants of SLC2A1 gene in t2dm and T2DM-nephropathy: Association study and meta-analysis
Stefanidis I., Tziastoudi M., Tsironi E.E., Dardiotis E., Tachmitzi S.V., Fotiadou A., Pissas G., Kytoudis K., Sounidaki M., Ampatzis G., Mertens P.R., Liakopoulos V., Eleftheriadis T., Hadjigeorgiou G.M., Santos M., Zintzaras E. (2018)An association study was conducted to investigate the relation between 14 variants of glucose transporter 1 gene (SLC2A1) and the risk of type 2 diabetes (T2DM) leading to nephropathy. We also performed a meta-analysis of ...